Skip to main content

Table 3 Steady-State Pharmacokinetic Parameters of Risperidone Plus 9-hydroxyrisperidone with 50 mg Once-Monthly or 25 mg Biweekly

From: Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

 

50 mg Once Monthly*

25 mg Biweekly [2]

Parameter

n

Mean ± SD

n

Mean ± SD

Cmin,ss, ng/mL

18

6.21 ± 3.1

21

11.3 ± 4.5

Cmax,ss, ng/mL

18

40.4 ± 15.3

21

22.7 ± 9.2

tmax,ss, h

18

240.2 ± 217.2

21

NA

AUCτ, ng·h/mL

17

12,027 ± 4241

21

5303

Cavg,ss, ng/mL

17

17.5 ± 6.1

21

15.8

FI, %

17

199 ± 55.8

21

69 ± 44

Cmax/Cmin ratio

18

7.4 ± 2.8

21

2.4 ± 1.8

  1. NA indicates not available.
  2. *Samples acquired between weeks 24 and 28.
  3. AUCÏ„: the dosing interval (Ï„) is 4 weeks for the present study and 2 weeks for Eerdekens M, et al.
Back to article page

Annals of General Psychiatry

ISSN: 1744-859X